Table 4.
Ongoing clinical trials focusing on patients with R/R AML or those who received haplo-SCT.
| ClinicalTrials.gov Identifier | Randomized study | Estimated Study Completion Date | Aim of the study |
|---|---|---|---|
| NCT04067180 | Yes | August 2028 | To evaluate whether haplo-SCT is as good as URD SCT for the treatment of AML. |
| NCT02782546 | No | January 30, 2024 | To explore the whether CIML NK could improve LFS of AML patients receiving haplo-SCT. |
| NCT04232241 | Yes | November 2024 | To compare anti-leukemic activity between MUDT (10/10) and haplo-SCT for patients with AL. |
| NCT03384225 | Yes | July 31, 2022 | To evaluate if CBA could decrease relapse after haplo-SCT in HR/R AML compared with FBA. |
| NCT03300492 | No | January 31, 2023 | Safety, Feasibility of Pre-emptive therapy With in Vitro Expanded NK Cells in AML/MDS Patients receiving Haplo-HSCT (Phase I/II). |
| NCT04678401 | No | October 31, 2023 | Immunosuppression-free Treg-cell Graft-engineered haplo-SCT in R/R AML/MDS (Phase I). |
| NCT04060277 | Yes | July 22, 2022 | To Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of haplo-SCT. |
| NCT04809181 | No | March 19, 2026 | To investigate the efficacy of Aza plus VEN for Prevention of Relapse in MRD-Positive Post allo-SCT AML/MDS Patients. |
| NCT04959903 | No | September 2026 | To explore the Safety and the Efficacy of SMART101 Injection to Accelerate IR After TCD allo-SCT in Patients With AL (Phase I/II). |
| NCT04599543 | No | November 15, 2023 | To investigate the Safety and Efficacy of IL3 CAR-T Cell Therapy for R/R Acute Myeloid Leukemia. |
| NCT04658004 | No | January 15, 2024 | The Safety and Efficacy of NKG2D CAR-T Cell Therapy for Patients With R/R AML. |
| NCT03473457 | No | December 31, 2022 | The CAR-T cells (single CAR-T or double CAR-T cells with CD33,CD38,CD56,CD123,CD117,CD133,CD34 or Mucl) for R/R AML |
| NCT04014881 | No | July 1, 2022 | To evaluate the safety and efficacy of anti-CD123 CAR-T cells in patients with R/R CD123+ AML. |
| NCT03971799 | No | December 2024 | To determine The safety and feasibility of anti-CD33 CAR-T cells in children and AYAs with R/R AML. |
| NCT04010877 | No | December 31, 2023 | The feasibility, safety and efficacy of multiple CAR T-cell therapy targeting CD123 or CD33 in patients with R/R AML. |
| NCT04272125 | No | July 1, 2023 | To evaluate the efficacy and safety of CD123-targeted CAR-T cell therapy for patients with R/R AML. |
| NCT04835519 | No | April 8, 2024 | To evaluate safety and tolerability of functionally enhanced CD33 CAR-T cells in patients with R/R AML. |
| NCT04219163 | No | July 31, 2038 | CAR T-cells for The Treatment of AML Expressing CLL-1 Antigen. |
| NCT04678336 | No | January 2036 | To explore the safety, feasibility, and efficacy of CART123 cells in pediatric subjects with R/R AML (Phase 1). |
| NCT04762485 | No | February 28, 2024 | This is a phase 1/2 study to evaluate the efficacy and safety of CAR-T cells targeting CD7 for patients with R/R CD7 positive AL. |
| NCT04766840 | No | December 1, 2023 | To Evaluate the Safety and Efficacy of Donor-derived CAR-T Cells for patients with R/R AML. |
| NCT03631576 | No | August 10, 2021 | This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with R/R AML. |
| NCT04318678 | No | July 1, 2025 | To explore the safety of autologous, CD123-CAR T cells in patients (≤21 years) with R/R CD123+ AML. |
| NCT04803929 | No | March 1, 2026 | To investigate the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with R/R AML (M4/M5). |
| NCT04789408 | No | January 2024 | A Phase 1 Open-label, Multicenter Study Evaluating an Autologous Anti-CLL-1 CAR T-cell therapy in Subjects With R/R AML. |
| NCT03190278 | No | October 2022 | Phase I first-in-human study evaluating the safety and efficacy of UCART targeting CD123 in patients with R/R AML. |
AML, acute myeloid leukemia; Haplo-SCT, haploidentical stem cell transplantation; URD SCT, unrelated donor SCT; CIML NK, cytokine-induced memory-like natural killer cells; LFS, leukemia-free survival; AL, acute leukemia; MUDT, human leukocyte antigen-matched unrelated donor transplantation; CBA, cladribine-based conditioning; FBA, fludarabine-based conditioning regimen; HR, high-risk; R, refractory; R/R, relapsed/refractory; Treg, regulatory T cells; CAR-T, chimeric antigen receptor (CAR)-expressing T cells; Aza, azacitidine; VEN, venetoclax; MRD, minimal residual disease; TCD, T cell depleted; SMART101, human T lymphocyte progenitor; IR, immune recovery; IL-3, interleukin-3.